The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 26, 2010
Filed:
May. 19, 2003
Lucilla Steinaa, Hørsholm, DK;
Jesper Haaning, Birkerod, DK;
Iben Dalum, Hørsholm, DK;
Peter Birk, Frederiksberg, DK;
Dana Leach, Copenhagen Ø, DK;
Klaus Gregorius Nielsen, Søborg, DK;
Gunilla Karlsson, Stockholm, SE;
Anand Gautam, Carina Heights, AU;
Søren Mouritsen, Oberägeri, CH;
Lucilla Steinaa, Hørsholm, DK;
Jesper Haaning, Birkerod, DK;
Iben Dalum, Hørsholm, DK;
Peter Birk, Frederiksberg, DK;
Dana Leach, Copenhagen Ø, DK;
Klaus Gregorius Nielsen, Søborg, DK;
Gunilla Karlsson, Stockholm, SE;
Anand Gautam, Carina Heights, AU;
Søren Mouritsen, Oberägeri, CH;
BN Immunotherapeutics, Inc., Mountain View, CA (US);
Abstract
A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.